University of Nove de Julho
uninove.brTotal trials
243
Active
45
Phase 3
3
Total enrollment
16,453
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Restoration with resin composite and polyvinyl crown | — | — | — | — | — | 1 | |
| Corticosteroid | — | — | — | — | — | 1 | |
| Ibuprofen | — | — | — | — | — | 1 | |
| Topical estrogen therapy based on estriol | — | — | — | — | — | 1 |
Next readouts
- 2024-07-20
- 2025-09-01
- 2026-11-10
- 2026-11-30
Top conditions
- Halitosis13
- Temporomandibular Disorder9
- Low Back Pain8
- Pain7
- Peripheral Arterial Disease5
- Xerostomia5
- Neck Pain5
- Photobiomodulation4
Frequently asked questions about University of Nove de Julho
- How many clinical trials does University of Nove de Julho have on ClinicalTrials.gov?
- University of Nove de Julho is listed as the lead sponsor on 243 clinical trials in ClinicalTrials.gov, 45 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Nove de Julho's trials are in Phase 3?
- 3 of University of Nove de Julho's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does University of Nove de Julho focus on?
- University of Nove de Julho's most-studied conditions on ClinicalTrials.gov are Halitosis, Temporomandibular Disorder, Low Back Pain, Pain, Peripheral Arterial Disease.
- When are University of Nove de Julho's next clinical trial readouts?
- University of Nove de Julho has 4 upcoming primary-completion readouts tracked here; the soonest is “Preventive Effect of Photobiomodulation in the Postoperative Period of Extractions of Retained Lower Third Molars”, expected around 2024-07-20.